<DOC>
	<DOCNO>NCT02663713</DOCNO>
	<brief_summary>Taken together result CHARISMA PEGASUS-TIMI54 , appear physician may consider extend beyond 1 year reinitiating treatment clopidogrel 75 mg od ticagrelor 60mg bid patient prior MI feature high ischemic low bleeding risk . Comparative clinical pharmacodynamic study , however , clopidogrel 75 mg od ticagrelor 60 mg bid chronic phase stable post MI patient perform . In platelet substudy PEGASUS-TIMI 54 , 180 patient receive &gt; 4 week study medication platelet reactivity assessment . Ticagrelor 60mg bid achieve high level peak trough platelet inhibition nearly patient , similar consistency effect compare 90mg bid . Platelet reactivity ( PRU ) significantly reduce ticagrelor 60mg bid compare placebo . In light , believe dedicate pharmacodynamic study ticagrelor 60 bid mg v clopidogrel 75 mg od PEGASUS-like population would informative practice clinician , thus set rationale conduct specifically design investigation . This prospective , randomize , single blind , single center , crossover study . Eligible patient undergo P2Y12 receptor antagonist therapy screen undergo 14-day minimum washout period randomization . Following screening/washout period ( visit 1 ) , patient randomize ( visit 2 , time 0 ) 1:1 fashion either clopidogrel 75 mg od ticagrelor 60 mg bid . Following 14Â±2 day ( visit 3 ) patient receive alternate treatment additional 14 day ( visit 4 ) . Platelet reactivity assessment perform VerifyNow P2Y12 reaction assay time 0 , prior first study drug dose . At visit 3 platelet function assess 2-4 hour post dose prior crossover . At visit 4 also platelet function assess 2-4 hour post study drug post dose . All patient receive concomitant aspirin ( 100 mg/d ) standard secondary prevention medication . The primary endpoint platelet reactivity measure P2Y12 reaction unit ( PRU ) end 2 study period ( pre-crossover post-crossover ) .</brief_summary>
	<brief_title>A Randomized , Pharmacodynamic Comparison Low Dose Ticagrelor Clopidogrel Patients With Prior Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Postmenopausal female ( defined absence vaginal bleed year ) male age &gt; 50 year 3 . A spontaneous MI ( ST Non ST segment elevation ) 1 3 year enrolment . In addition , least one follow highrisk feature : age 65 year old , diabetes mellitus require medication , second prior spontaneous MI , multivessel coronary artery disease , nonend stage renal disease ( estimate creatinine clearance &lt; 60 ml per minute ) . 1 . Planned use P2Y12 receptor antagonist , dipyridamole , cilostazol , anticoagulant therapy study period ; 2 . Known allergy , intolerance , hypersensitivity ticagrelor clopidogrel excipients , 3 . Active pathological bleeding , severe hepatic impairment , bleed disorder history ischemic stroke intracranial bleeding , central nervous system tumor , intracranial vascular abnormality ; 4 . Gastrointestinal bleeding within previous 6 month major surgery within previous 30 day ; 5 . Concomitant use potent Cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin voriconazole , grapefruit juice 1 litre daily ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , inducer ( carbamazepine , dexamethasone , phenobarbital , phenytoin , rifampin , rifapentine ) . 6 . Increased risk bradycardic event ( e.g . know sick sinus syndrome third degree AV block previous document syncope suspect due bradycardia unless treat pacemaker ) . 7 . Inability adhere followup requirement reason condition investigator feel would place patient increase risk investigational therapy initiate .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>MI</keyword>
</DOC>